Somatostatin receptor (SSTR) imaging has brought about impactful changes in clinical management of neuroendocrine tumors (NETs), including pheochromocytoma and paraganglioma (PPGL) ([ 1 ][1] , [ 2 ][2]). It allows tumor detection and disease characterization and is mandatory for selecting patients
No takes yet. Share an insight, caveat, or question.
Jha et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: